A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) - Miller,V.; O'Connor,P.; Soh,C.; Kabbinavar,F. (J Clin Oncol, 2009)